

# Nelson N Stone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/590144/publications.pdf>

Version: 2024-02-01

263  
papers

8,559  
citations

32410

55  
h-index

60403

85  
g-index

265  
all docs

265  
docs citations

265  
times ranked

4527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy. <i>Brachytherapy</i> , 2022, 21, 460-467.	0.2	2
2	Remote surgical education using synthetic models combined with an augmented reality headset. <i>Surgery Open Science</i> , 2022, 10, 27-33.	0.5	5
3	Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI-RADS 3-5 regions of interest. <i>BJUI Compass</i> , 2021, 2, 395-401.	0.7	2
4	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2020, 112, 179-190.	3.0	71
5	Transperineal mapping biopsy improves selection of brachytherapy boost for men with localized prostate cancer. <i>Brachytherapy</i> , 2020, 19, 33-37.	0.2	0
6	Prolonged hormonal therapy and external beam radiation independently increase the risk of Persistent Hypogonadism in men treated with prostate brachytherapy. <i>Brachytherapy</i> , 2020, 19, 210-215.	0.2	0
7	I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes. <i>Brachytherapy</i> , 2020, 19, 567-573.	0.2	1
8	Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation. <i>Brachytherapy</i> , 2020, 19, 275-281.	0.2	5
9	Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy. <i>BJU International</i> , 2019, 123, 277-283.	1.3	4
10	Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. <i>Brachytherapy</i> , 2019, 18, 332-337.	0.2	1
11	Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (>60 years) with localized prostate cancer. <i>Brachytherapy</i> , 2019, 18, 192-197.	0.2	7
12	The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. <i>Journal of Urology</i> , 2019, 202, 264-271.	0.2	12
13	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 271-271.	0.2	0
14	Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. <i>BJU International</i> , 2018, 121, 781-790.	1.3	26
15	Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. <i>BJU International</i> , 2018, 121, 774-780.	1.3	12
16	Low dose rate prostate brachytherapy in younger men. <i>BJU International</i> , 2018, 121, 2-2.	1.3	0
17	Factors influencing long-term urinary symptoms after prostate brachytherapy. <i>BJU International</i> , 2018, 122, 831-836.	1.3	5
18	Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. <i>Brachytherapy</i> , 2018, 17, 874-881.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison. <i>Reviews in Urology</i> , 2018, 20, 19-25.	0.9	28
20	The 3DBiopsy Prostate Biopsy System: Preclinical Investigation of a Needle, Actuator, and Specimen Collection Device Allowing Sampling of Individualized Prostate Lengths Between 20 and 60%mm. <i>Urology</i> , 2017, 107, 257-261.	0.5	2
21	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). <i>Urology</i> , 2017, 104, 150-159.	0.5	29
22	MP05-10 LONG-TERM URINARY SYMPTOMS FOLLOWING PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
23	MP05-12 RACE, COMORBIDITIES AND LONG-TERM ERECTILE FUNCTION AFTER PROSTATE BRACHYTHERAPY: WHAT ROLE DOES EACH HAVE ON POTENCY PRESERVATION. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
24	PD45-02 VALIDATION STUDY OF THE MALE ANDROGEN DEFICIENCY SYNDROME (MADS) SCREENING QUESTIONNAIRE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
25	PD72-08 DISTANT RECURRENCE PATTERNS IN PATIENTS WITH PROSTATE CANCER INITIALLY TREATED WITH BRACHYTHERAPY WHO EXPERIENCED BIOCHEMICAL FAILURE.. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
26	MP05-07 PROLONGED HORMONAL THERAPY AND EXTERNAL BEAM RADIATION INDEPENDENTLY INCREASE THE RISK OF PERSISTENT HYPOGONADISM IN MEN TREATED WITH PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
27	MP05-11 PROSTATE BRACHYTHERAPY AND TURP: PRE-IMPLANT SYMPTOM SEVERITY HAS GREATER INFLUENCE THAN TIMING OF TURP ON LONG-TERM URINARY QUALITY OF LIFE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
28	MP05-15 HETEROGENEOUS OUTCOMES IN GLEASON SCORE 7 PROSTATE CANCER PATIENTS ARE ASSOCIATED WITH DIFFERENTIAL BIOLOGICAL EFFECTIVE DOSE AND HORMONE UTILIZATION. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
29	MP69-04 IDENTIFICATION OF MODIFIABLE RISK FACTORS ASSOCIATED WITH PATIENT-REPORTED ERECTILE DYSFUNCTION TO ENHANCE PATIENT HEALTH COUNSELING AND SEXUAL QUALITY OF LIFE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
30	Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 654-661.	0.8	7
31	Detecting, Localizing, and Treating the Multiparametric Magnetic Resonance Imaging Invisible Lesion: Utilizing Three-Dimensional Transperineal Mapping. <i>Current Clinical Urology</i> , 2017, , 239-250.	0.0	0
32	The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 730-735.	0.2	2
33	MP14-03 LONG-TERM OUTCOMES OF PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
34	MP76-20 PROSPECTIVE LONG-TERM OUTCOME OF ERECTILE FUNCTION IN MEN TREATED BY PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
35	PD26-12 COMPLICATIONS ASSOCIATED WITH TRANSRECTAL AND TRANSPERINEAL PROSTATE MAPPING BIOPSY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
36	MP57-07 TRANSPERINEAL PROSTATE MAPPING BIOPSY CORRECTLY IDENTIFIES CANDIDATES FOR RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0

#	ARTICLE	IF	CITATIONS
37	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	2.7	69
38	Urinary Incontinence Following Prostate Brachytherapy. Urology, 2016, 95, 151-157.	0.5	11
39	A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate Cancer. , 2016, , 151-172.		0
40	3D Biopsy: A New Method to Diagnose Prostate Cancer. , 2016, , 83-91.		2
41	Transperineal Biopsy Technique. , 2016, , 69-82.		0
42	MP71-11 URINARY SYMPTOMS AND MEDICATIONS USED IN MEN ATTENDING A NATIONAL HEALTH SCREENING PROGRAM. Journal of Urology, 2015, 193, .	0.2	0
43	MP60-08 PROSTATE HEALTH INDEX IS AN EFFECTIVE MARKER FOR RISK STRATIFICATION OF PROSTATE CANCER PATIENTS. Journal of Urology, 2015, 193, .	0.2	0
44	MP62-16 FACTORS AFFECTING METASTASIS AND LONG-TERM SURVIVAL FOLLOWING PROSTATE BRACHYTHERAPY. Journal of Urology, 2015, 193, .	0.2	0
45	MP6-06 PROSTATE HEALTH INDEX PREDICTS UPGRADING OF MEN ON 5-ALPHA REDUCTASE INHIBITORS. Journal of Urology, 2015, 193, .	0.2	1
46	MP24-10 DECLINING USE OF URINARY HERBAL AND VITAMIN SUPPLEMENTS AMONG U.S. MEN IN LONGITUDINAL NATIONAL PROSTATE CANCER SCREENING COHORTS. Journal of Urology, 2015, 193, .	0.2	0
47	MP87-04 TIMING OF SALVAGE ANDROGEN DEPRIVATION THERAPY FOLLOWING PROSTATE RADIOTHERAPY DOES NOT ADVERSELY AFFECT ALL-CAUSE OR PROSTATE CANCER SPECIFIC SURVIVAL. Journal of Urology, 2015, 193, .	0.2	0
48	MP62-12 NOMOGRAMS PREDICTING 15-YEAR PROSTATE CANCER SPECIFIC MORTALITY AND PROSTATE CANCER RECURRENCE FOLLOWING DEFINITIVE BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER.. Journal of Urology, 2015, 193, .	0.2	0
49	MP48-09 RESULTS OF TRANSPERINEAL MAPPING BIOPSY OF THE PROSTATE. Journal of Urology, 2015, 193, .	0.2	0
50	V4-09 TRANSPERINEAL PROSTATE BIOPSY WITH NEW MAPPING SOFTWARE. Journal of Urology, 2015, 193, .	0.2	0
51	Diagnosis and management of local recurrence after low-dose-rate brachytherapy. Brachytherapy, 2015, 14, 124-130.	0.2	12
52	PD2-04 TESTOSTERONE REPLACEMENT THERAPY (TRT) INFREQUENTLY USED IN HYPOGONADAL MEN. Journal of Urology, 2015, 193, .	0.2	0
53	MP62-11 IMPROVED LOCAL CONTROL IS ASSOCIATED WITH BETTER LONG TERM SURVIVAL FOLLOWING PROSTATE BRACHYTHERAPY. Journal of Urology, 2015, 193, .	0.2	0
54	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. European Journal of Cancer, 2015, 51, 2345-2367.	1.3	81

#	ARTICLE	IF	CITATIONS
55	To screen or nor to screen: the prostate cancer dilemma. Asian Journal of Andrology, 2015, 17, 44.	0.8	4
56	PSA levels of >1.5-4 ng/mL in a men's health evaluation as a method for informed decision making.. Journal of Clinical Oncology, 2015, 33, e16039-e16039.	0.8	0
57	Male Androgen Deficiency Syndrome Screening Questionnaire: A Simplified Instrument to Identify Testosterone-Deficient Men. Journal of Men's Health, 2014, 11, 28-37.	0.1	3
58	Findings at Cystoscopy Performed for Cause After Prostate Brachytherapy. Urology, 2014, 83, 1350-1355.	0.5	15
59	Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-Year experience at Mount Sinai Medical Center. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e1-38.e7.	0.8	42
60	Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiotherapy and Oncology, 2014, 110, 261-267.	0.3	2
61	MP45-12 OVERESTIMATION OF BIOCHEMICAL FREEDOM FROM FAILURE (BFFF) USING THE PHOENIX DEFINITION FOLLOWING RADIATION THERAPY (RT) FOR PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	1
62	Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer. Urology, 2014, 83, 664-669.	0.5	86
63	Moving Forward the State of the Art in Prostate Cancer Treatment: Targeted Focal Therapy. Urology Practice, 2014, 1, 156-164.	0.2	1
64	15-Year Cause Specific and All-Cause Survival Following Brachytherapy for Prostate Cancer: Negative Impact of Long-Term Hormonal Therapy. Journal of Urology, 2014, 192, 754-759.	0.2	27
65	Does dose matter? Editorial comments to Morris et al. Whole prostate D90 and V100: A dose response analysis of 2000 consecutive 125I monotherapy cases. Brachytherapy, 2014, 13, 42-43.	0.2	9
66	PD14-05 IMPACT OF NEOADJUVANT HORMONE THERAPY (NHT) ON ALL CAUSE SURVIVAL (ACS) FOLLOWING PROSTATE BRACHYTHERAPY (PB). Journal of Urology, 2014, 191, .	0.2	0
67	Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer. Current Bladder Dysfunction Reports, 2013, 8, 236-241.	0.2	1
68	The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU International, 2013, 112, E44-50.	1.3	15
69	Predictive Factors and Management of Rectal Bleeding Side Effects Following Prostate Cancer Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 842-847.	0.4	49
70	1203 PREDICTORS OF URINARY INCONTINENCE FOLLOWING PROSTATE BRACHYTHERAPY. Journal of Urology, 2013, 189, .	0.2	0
71	723 RISK-ADJUSTED ACTUAL HOSPITAL COSTS OF THE PRIMARY TREATMENT OF PROSTATE CANCER: A CONTEMPORARY EXPERIENCE OF A MULTIDISCIPLINARY CANCER CENTER. Journal of Urology, 2013, 189, .	0.2	0
72	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms After Radiotherapy for Prostate Cancer. Journal of Urology, 2013, 190, 102-108.	0.2	55

#	ARTICLE	IF	CITATIONS
73	Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control, and morbidity. <i>Brachytherapy</i> , 2013, 12, 217-221.	0.2	21
74	Long-term Outcomes and Toxicity in Patients Treated With Brachytherapy for Prostate Adenocarcinoma Younger Than 60 Years of Age at Treatment With Minimum 10 Years of Follow-up. <i>Urology</i> , 2013, 81, 364-369.	0.5	31
75	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e21-e28.	0.4	59
76	Editorial Comment from Dr Stone to Interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. <i>International Journal of Urology</i> , 2013, 20, 148-148.	0.5	2
77	Rebuttal to Drs. Spratt and Zelefsky. <i>Brachytherapy</i> , 2013, 12, 400.	0.2	2
78	Counterpoint: Is there a need for supplemental XRT in intermediate-risk prostate cancer patients?. <i>Brachytherapy</i> , 2013, 12, 393-397.	0.2	3
79	Transurethral Resection Versus Intermittent Catheterization in Patients with Retention after Combined Brachytherapy/External Beam Radiotherapy for Prostate Cancer: Transurethral Resection. <i>Journal of Urology</i> , 2013, 189, 800-801.	0.2	5
80	Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2013, 107, 372-376.	0.3	70
81	1202 FACTORS AFFECTING 15-YEAR SURVIVAL FOLLOWING PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
82	1376 RISK OF URINARY INCONTINENCE FOLLOWING POST-BRACHYTHERAPY TRANSURETHRAL RESECTION OF PROSTATE (TURP) AND CORRELATION WITH CLINICAL AND TREATMENT PARAMETERS. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
83	1391 MALE ANDROGEN DEFICIENCY (MAD) SCREENING QUESTIONNAIRE: A SIMPLIFIED TOOL TO IDENTIFY HYPOGONADAL MEN. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
84	Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. <i>BJU International</i> , 2013, 111, E43-7.	1.3	9
85	Haematuria after prostate brachytherapy. <i>BJU International</i> , 2013, 111, E319-24.	1.3	8
86	Intensity-Modulated Radiotherapy Causes Fewer Side Effects than Three-Dimensional Conformal Radiotherapy When Used in Combination With Brachytherapy for the Treatment of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 630-635.	0.4	25
87	PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 600-607.	0.4	36
88	Predictors of Metastatic Disease After Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 645-652.	0.4	9
89	Factors Influencing Urinary Symptoms 10 Years After Permanent Prostate Seed Implantation. <i>Journal of Urology</i> , 2012, 187, 117-123.	0.2	30
90	512 LONG-TERM LOCAL FAILURE FOLLOWING PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
91	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. <i>Brachytherapy</i> , 2012, 11, 6-19.	0.2	399
92	Biopsy and implantation of the seminal vesicles. <i>Brachytherapy</i> , 2012, 11, 334-340.	0.2	6
93	1928 REPEAT PSA AND DRE TESTING IN A PROSTATE CANCER SCREENING ENVIRONMENT. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
94	1139 RELATIONSHIP BETWEEN SERUM TESTOSTERONE, BMI, FAT CONSUMPTION, AND EXERCISE. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
95	Role of Testosterone in Managing Advanced Prostate Cancer. <i>Urology</i> , 2012, 80, 754-762.	0.5	22
96	Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. <i>BMC Cancer</i> , 2012, 12, 110.	1.1	41
97	Long-term potency preservation following brachytherapy for prostate cancer. <i>BJU International</i> , 2012, 110, 221-225.	1.3	32
98	Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure. <i>BJU International</i> , 2012, 110, 1257-1261.	1.3	11
99	Actual total hospital costs of primary localized prostate cancer treatments analyzed by risk group.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15164-e15164.	0.8	0
100	1583 AMERICAN UROLOGICAL ASSOCIATION SYMPTOM SCORE NOCTURIA QUESTION AS AN INDEPENDENT INDICATOR OF BPH IN A SCREENING POPULATION. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
101	1110 FACTORS INFLUENCING URINARY FUNCTION DURING THE FIRST 10 YEARS FOLLOWING PERMANENT PROSTATE SEED IMPLANTATION. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
102	344 GENETIC FACTORS INFLUENCE TIME TO UNDETECTABLE PSA IN MEN WITH PROSTATE CANCER TREATED BY RADIOTHERAPY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
103	2042 PROSTATE CANCER AND MEN'S HEALTH SCREENING: COMPARISON OF THE SCREENING POPULATIONS FROM 2003 AND 2009. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
104	Influence of Pretreatment and Treatment Factors on Intermediate to Long-Term Outcome After Prostate Brachytherapy. <i>Journal of Urology</i> , 2011, 185, 495-500.	0.2	64
105	Methods of Developing UWIN, the Modified American Urological Association Symptom Score. <i>Journal of Urology</i> , 2011, 186, 940-944.	0.2	12
106	Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity. <i>Current Urology Reports</i> , 2011, 12, 237-242.	1.0	18
107	Impact of race on biochemical disease recurrence after prostate brachytherapy. <i>Cancer</i> , 2011, 117, 5589-5600.	2.0	29
108	Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. <i>Brachytherapy</i> , 2011, 10, 261-268.	0.2	21



#	ARTICLE	IF	CITATIONS
109	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1061-1065.	0.4	59
110	Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?. <i>Brachytherapy</i> , 2010, 9, 114-118.	0.2	13
111	Local Control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 355-360.	0.4	90
112	Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1315-1321.	0.4	48
113	Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1338-1344.	0.4	142
114	Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms (SNPs) Associated With the Development of Erectile Dysfunction in African-American Men After Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1292-1300.	0.4	143
115	588 TREATMENT OF GLEASON GRADE 5 PROSTATE CANCER BY COMBINED MODALITY RADIATION THERAPY. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
116	Does Neoadjuvant Hormonal Therapy Improve Urinary Function When Given to Men With Large Prostates Undergoing Prostate Brachytherapy?. <i>Journal of Urology</i> , 2010, 183, 634-640.	0.2	26
117	Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation. <i>Journal of Urology</i> , 2010, 183, 546-551.	0.2	33
118	Current Topics in the Treatment of Prostate Cancer with Low-Dose-Rate Brachytherapy. <i>Urologic Clinics of North America</i> , 2010, 37, 83-96.	0.8	17
119	Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 16-22.	0.4	60
120	Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. <i>BJU International</i> , 2009, 104, 1631-1636.	1.3	60
121	Effect of Family History on Outcomes in Patients Treated With Definitive Brachytherapy for Clinically Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 24-29.	0.4	9
122	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 341-346.	0.4	126
123	Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy. <i>Pathology Research and Practice</i> , 2009, 205, 843-846.	1.0	5
124	There Is No Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Real-Time Low-Dose-Rate Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1468-1474.	0.4	39
125	Prognostic Significance of 5-Year PSA Value for Predicting Prostate Cancer Recurrence After Brachytherapy Alone and Combined With Hormonal Therapy and/or External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 753-758.	0.4	42
126	Long-term Outcomes and Toxicity of Salvage Brachytherapy for Local Failure after Initial Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, S157-S158.	0.4	0



#	ARTICLE	IF	CITATIONS
127	Focal Therapy for Prostate Cancer Is a Reasonable Treatment Option in Properly Selected Patients: Oppose. <i>Urology</i> , 2009, 74, 731-734.	0.5	1
128	THE INCIDENCE AND CHARACTERIZATION OF THE METABOLIC SYNDROME IN A PROSTATE CANCER SCREENING POPULATION. <i>Journal of Urology</i> , 2009, 181, 803-804.	0.2	0
129	PREDICTORS OF THE ANDROGEN DEFICIENCY IN MEN (ADAM) SYNDROME IN A PROSTATE CANCER SCREENING POPULATION. <i>Journal of Urology</i> , 2009, 181, 368-368.	0.2	0
130	Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. <i>Brachytherapy</i> , 2008, 7, 217-222.	0.2	17
131	Local Control Following Permanent Prostate Brachytherapy (PPB): Effect of High Biologic Effective Dose on Biopsy Results and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S136-S137.	0.4	1
132	10 Years of Urinary Function Following Low Dose Rate Prostate Brachytherapy: An Analysis of International Prostate Symptom Scores. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S100-S101.	0.4	0
133	TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 752-759.	0.4	64
134	125I Monotherapy Using D90 Implant Doses of 180 Gy or Greater. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 96-101.	0.4	60
135	In Reply to Drs. Oton and Oton. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 962-963.	0.4	0
136	Long-term Outcomes for Patients with Gleason Scores 8-10 Prostate Cancer Treated with Combination Brachytherapy, External Beam Irradiation and Hormonal Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S290.	0.4	1
137	A Pretreatment PSA Level of 7 to 10 Ng/mL is an Independent Predictor of Adverse Biochemical Disease Free Survival among Low Risk Prostate Cancer Patients Treated with I-125 Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S304-S305.	0.4	0
138	Defining the Risk of Developing Grade 2 Proctitis Following Combined Modality Therapy using a Rectal Dose-volume Histogram Analysis and Biologic Equivalent Dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S333.	0.4	2
139	Association of Single Nucleotide Polymorphisms in SOD2, XRCC1 and XRCC3 with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer. <i>Radiation Research</i> , 2008, 170, 49-59.	0.7	81
140	Brachytherapy for the Treatment of Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 302-312.	1.0	38
141	Long-Term Urinary, Sexual, and Rectal Morbidity in Patients Treated with Iodine-125 Prostate Brachytherapy Followed Up for a Minimum of 5 Years. <i>Urology</i> , 2007, 69, 338-342.	0.5	113
142	Patterns of Local Failure Following Prostate Brachytherapy. <i>Journal of Urology</i> , 2007, 177, 1759-1764.	0.2	40
143	The Effect of Brachytherapy, External Beam Irradiation and Hormonal Therapy on Prostate Volume. <i>Journal of Urology</i> , 2007, 177, 925-928.	0.2	20
144	Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. <i>Brachytherapy</i> , 2007, 6, 38-43.	0.2	12

#	ARTICLE	IF	CITATIONS
145	A Genetically Determined Dose-Volume Histogram Predicts for Rectal Bleeding among Patients Treated With Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1410-1416.	0.4	54
146	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1472-1477.	0.4	92
147	Comparisons of PSA Failure Definitions Following Trimodality Therapy for Intermediate to High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S344-S345.	0.4	1
148	Dose Response Study of Pd-103 Prostate Seed Implantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S349-S350.	0.4	0
149	Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S351-S352.	0.4	0
150	The Effect of Family History on Outcome in Patients Treated With Low-Dose Rate Brachytherapy for Clinically Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S370-S371.	0.4	0
151	Young Men have Equivalent Biochemical Outcomes Compared to Older Men After Treatment With Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S90-S91.	0.4	1
152	A Validation Study to Examine the Correlation Between Possession of Variants in the ATM Gene With the Development of Erectile Dysfunction in Prostate Cancer Patients Treated With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S29.	0.4	4
153	Prognostic Significance of the 5-Year PSA Value for Predicting Prostate Cancer Recurrence Following Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S176-S177.	0.4	0
154	Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at 7 years of follow-up. <i>BJU International</i> , 2007, 100, 362-367.	1.3	36
155	Assessment of postbrachytherapy sexual function: A comparison of the IIEF-5 and the MSEFS. <i>Brachytherapy</i> , 2007, 6, 26-33.	0.2	21
156	1763: Multicenter Analysis of Outcomes in Patients Treated with Permanent Prostate Brachytherapy: Effect of PSA Failure Definition and Dose on Biochemical Defined Relapse. <i>Journal of Urology</i> , 2007, 177, 586-586.	0.2	1
157	Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. <i>BJU International</i> , 2006, 98, 979-981.	1.3	19
158	Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 527-533.	0.4	221
159	Disease-specific survival following the brachytherapy management of prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 810-816.	0.4	72
160	Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 424-429.	0.4	45
161	Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 389-394.	0.4	43
162	103. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S58.	0.4	1

#	ARTICLE	IF	CITATIONS
163	121. International Journal of Radiation Oncology Biology Physics, 2006, 66, S69.	0.4	0
164	Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment. Journal of Clinical Oncology, 2006, 24, 3081-3088.	0.8	52
165	ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 196-202.	0.4	88
166	Impact of Low Dose Rate Prostate Brachytherapy on the Sexual Health of Men with Normal Pre-treatment Sexual Function; an Analysis at Seven-years Minimum Follow-up. International Journal of Radiation Oncology Biology Physics, 2005, 63, S80-S81.	0.4	0
167	Biologically Effective Dose Values for Prostate Brachytherapy: Effects on PSA Failure and Post-Treatment Biopsy Results. International Journal of Radiation Oncology Biology Physics, 2005, 63, S292.	0.4	0
168	C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU International, 2005, 95, 961-962.	1.3	73
169	Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer. BJU International, 2005, 96, 328-329.	1.3	8
170	Seminal Vesicles: Diagnosis, Staging, Surgery, and Management. , 2005, , 555-564.		0
171	INTERMEDIATE TERM BIOCHEMICAL-FREE PROGRESSION AND LOCAL CONTROL FOLLOWING 125 IODINE BRACHYTHERAPY FOR PROSTATE CANCER. Journal of Urology, 2005, 173, 803-807.	0.2	69
172	PROSTATE CANCER IN A LARGE PROSTATE IS ASSOCIATED WITH A DECREASED PROSTATE SPECIFIC ANTIGEN FAILURE RATE AFTER BRACHYTHERAPY. Journal of Urology, 2005, 173, 79-81.	0.2	15
173	Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy. Urology, 2005, 66, 119-123.	0.5	40
174	Transrectal Ultrasound-Guided Permanent Prostate Seed Implantation. , 2005, , 11-31.		0
175	Serum Interleukin-8 is Elevated in Men with Prostate Cancer and Bone Metastases. Technology in Cancer Research and Treatment, 2004, 3, 411-411.	0.8	81
176	Influence of prostate volume on dosimetry results in real-time 125I seed implantation. International Journal of Radiation Oncology Biology Physics, 2004, 58, 292-299.	0.4	41
177	Combined modality treatment in the management of high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1352-1359.	0.4	91
178	Does prior transurethral resection of prostate compromise brachytherapy quality: A dosimetric analysis. International Journal of Radiation Oncology Biology Physics, 2004, 60, 648-653.	0.4	9
179	Morbidity After Brachytherapy for Prostate Adenocarcinoma. Mayo Clinic Proceedings, 2004, 79, 946-947.	1.4	1
180	How the Addition of Hormones Improves Outcome: Hormone Therapy and Radiotherapy. European Urology Supplements, 2004, 3, 32-36.	0.1	0

#	ARTICLE	IF	CITATIONS
181	Hormonal therapy reduces the risk of post-implant urinary retention in symptomatic prostate cancer patients with glands larger than 50 cc. International Journal of Radiation Oncology Biology Physics, 2004, 60, S451-S451.	0.4	0
182	Does local control impact prostate cancer specific survival (PCSS) within the first 10 years following brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, S184-S184.	0.4	0
183	Combined Modality Therapy With Brachytherapy and External Beam Irradiation in the Management of Localized Prostate Cancer. , 2004, , 233-255.		0
184	Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. International Journal of Radiation Oncology Biology Physics, 2003, 57, 645-653.	0.4	140
185	Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy, 2003, 2, 17-25.	0.2	72
186	Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy, 2003, 2, 32-39.	0.2	17
187	Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. International Journal of Radiation Oncology Biology Physics, 2003, 56, 448-453.	0.4	125
188	Urinary symptom flare following I-125 prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1085-1092.	0.4	74
189	Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urologic Clinics of North America, 2003, 30, 351-362.	0.8	6
190	Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the t1307k allele of the APC(adenopolyposis coli) gene. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 101-104.	0.8	4
191	Re: Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. Journal of the National Cancer Institute, 2002, 94, 1893-1893.	3.0	3
192	Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 73-76.	0.8	19
193	Importance of Post-Implant Dosimetry in Permanent Prostate Brachytherapy. European Urology, 2002, 41, 434-439.	0.9	77
194	Permanent seed implantation for localized adenocarcinoma of the prostate. Current Urology Reports, 2002, 3, 201-206.	1.0	22
195	Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. International Journal of Radiation Oncology Biology Physics, 2002, 52, 444-452.	0.4	123
196	Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate, 2002, 50, 1-3.	1.2	71
197	Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy, 2002, 1, 2-10.	0.2	17
198	What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy, 2002, 1, 83-89.	0.2	59

#	ARTICLE	IF	CITATIONS
199	Prostate gland motion and deformation caused by needle placement during brachytherapy. <i>Brachytherapy</i> , 2002, 1, 154-160.	0.2	64
200	Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. <i>Journal of Urology</i> , 2002, 168, 2431-3.	0.2	13
201	PENILE ERECTILE FUNCTION AFTER PERMANENT RADIOACTIVE SEED IMPLANTATION FOR TREATMENT OF PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 165, 436-439.	0.2	189
202	Defining the risk of developing Grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 335-341.	0.4	211
203	Clinical staging of prostate cancer: Reproducibility and clarification of issues. <i>International Journal of Cancer</i> , 2001, 96, 198-209.	2.3	22
204	Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 1422-1430.	0.4	223
205	The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma. , 2000, 88, 2105-2109.		79
206	The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy. <i>Cancer</i> , 2000, 89, 1829-1834.	2.0	44
207	Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 899-906.	0.4	102
208	Prostate brachytherapy in patients with prostate volumes $\leq 50$ cm <sup>3</sup> : dosimetic analysis of implant quality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 1199-1204.	0.4	68
209	Body mass, age, and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients. <i>Cancer Genetics and Cytogenetics</i> , 2000, 122, 131-133.	1.0	12
210	Biopsy Results after Real-Time Ultrasound-Guided Transperineal Implants for Stage T1-T2 Prostate Cancer. <i>Journal of Endourology</i> , 2000, 14, 375-380.	1.1	11
211	Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 385-389.	0.4	24
212	PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. <i>Radiation Oncology Investigations</i> , 1999, 7, 30-35.	1.3	18
213	PROSTATE BRACHYTHERAPY: TREATMENT STRATEGIES. <i>Journal of Urology</i> , 1999, 162, 421-426.	0.2	91
214	PERMANENT RADIOACTIVE SEED IMPLANTATION IN THE TREATMENT OF PROSTATE CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 489-501.	0.9	14
215	PROSTATE BRACHYTHERAPY. <i>Journal of Urology</i> , 1999, , 421-426.	0.2	2
216	Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. <i>Radiation Oncology Investigations</i> , 1998, 6, 135-141.	1.3	104

#	ARTICLE	IF	CITATIONS
217	PERINEURAL INVASION AND SEMINAL VESICLE INVOLVEMENT PREDICT PELVIC LYMPH NODE METASTASIS IN MEN WITH LOCALIZED CARCINOMA OF THE PROSTATE. <i>Journal of Urology</i> , 1998, 160, 1722-1726.	0.2	71
218	IDENTIFICATION OF PATIENTS AT INCREASED RISK FOR PROLONGED URINARY RETENTION FOLLOWING RADIOACTIVE SEED IMPLANTATION OF THE PROSTATE. <i>Journal of Urology</i> , 1998, 160, 1379-1382.	0.2	258
219	IDENTIFICATION OF PATIENTS AT INCREASED RISK FOR PROLONGED URINARY RETENTION FOLLOWING RADIOACTIVE SEED IMPLANTATION OF THE PROSTATE. <i>Journal of Urology</i> , 1998, , 1379-1382.	0.2	9
220	PERINEURAL INVASION AND SEMINAL VESICLE INVOLVEMENT PREDICT PELVIC LYMPH NODE METASTASIS IN MEN WITH LOCALIZED CARCINOMA OF THE PROSTATE. <i>Journal of Urology</i> , 1998, , 1722-1726.	0.2	2
221	Laparoscopic Urologic Surgery Outcome Assessment. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 1997, 7, 77-86.	0.5	14
222	LAPAROSCOPIC PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER: COMPARISON OF THE EXTENDED AND MODIFIED TECHNIQUES. <i>Journal of Urology</i> , 1997, 158, 1891-1894.	0.2	194
223	Comparison of perspectives on prostate cancer: analyses of survey data. <i>Urology</i> , 1997, 50, 366-372.	0.5	118
224	A new technique for performing syed-neblett template interstitial implants for gynecologic malignancies using transrectal-ultrasound guidance. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 819-825.	0.4	77
225	1012 Dose response for iodine - 125 prostate implants. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 221.	0.4	7
226	The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, 13, 454-460.		53
227	Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. <i>Urology</i> , 1996, 48, 234-239.	0.5	159
228	Seminal vesicle biopsy: Accuracy and implications for staging of prostate cancer. <i>Urology</i> , 1996, 48, 757-761.	0.5	45
229	A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multicenter study. <i>Urology</i> , 1996, 47, 497-504.	0.5	25
230	Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 267-272.	0.4	118
231	Cisplatin-based chemotherapy in renal transplant recipients: A case report and a review of the literature. , 1996, 77, 160-163.		19
232	Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. , 1996, 77, 2386-2392.		121
233	Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. , 1996, 77, 2386.		1
234	A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 219-225.	0.4	240



#	ARTICLE	IF	CITATIONS
235	Prostate brachytherapy:Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry. Radiation Oncology Investigations, 1995, 3, 185-195.	1.3	55
236	Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer. International Journal of Radiation Oncology Biology Physics, 1995, 33, 815-821.	0.4	42
237	Laparoscopic Pelvic Lymph Node Dissection Combined with Real-time Interactive Transrectal Ultrasound Guided Transperineal Radioactive Seed Implantation of the Prostate. Journal of Urology, 1995, 153, 1555-1560.	0.2	52
238	Indications for Seminal Vesicle Biopsy and Laparoscopic Pelvic Lymph Node Dissection in Men With Localized Carcinoma of Prostate. Journal of Urology, 1995, 154, 1392-1396.	0.2	67
239	Screening for prostate cancer by digital rectal examination and prostate-specific antigen. Urology, 1994, 44, 18-25.	0.5	27
240	CONSERVATIVE TREATMENT OF TYPE III RENAL TRAUMA. Journal of Trauma, 1994, 36, 491-494.	2.3	52
241	Persistent Maternal Hydronephrosis After Intra-Abdominal Pregnancy. Journal of Urology, 1994, 152, 1196-1198.	0.2	6
242	Effect of Age, Educational Status, Ethnicity and Geographic Location on Prostate Symptom Scores. Journal of Urology, 1994, 152, 1498-1500.	0.2	36
243	Bladder rupture associated with pelvic fracture due to blunt trauma. Urology, 1993, 41, 531-533.	0.5	56
244	Renal angiomyolipoma associated with neurofibromatosis and primary carcinoid of mesentery. Urology, 1993, 41, 66-71.	0.5	13
245	Laparoscopic retroperitoneal lymph node dissection in stage a nonseminomatous testis cancer. Urology, 1993, 42, 610-614.	0.5	25
246	Isograft Bladder Mucosal Transplantation for Hypospadias Repair in Identical Twins. Journal of Urology, 1993, 150, 1884-1885.	0.2	4
247	A Spermatic Cord Hematoma Secondary to Varicocele Rupture from Blunt Abdominal Trauma: A Case Report and Review. Journal of Urology, 1993, 149, 602-603.	0.2	15
248	Covered Exstrophy with Sequestered Colonic Remnant. Journal of Urology, 1993, 150, 185-187.	0.2	6
249	Flutamide in BPH. , 1993, , 515-521.		0
250	Laparoscopy for evaluation of cryptorchid testis. Urology, 1992, 40, 256-258.	0.5	24
251	Value of serum alkaline phosphatase and radionuclide bone scans in patients with renal cell carcinoma. Urology, 1991, 38, 220-222.	0.5	23
252	Role of immunotherapy in the treatment of bladder and renal cell carcinoma. Journal of Surgical Oncology, 1991, 7, 239-243.	1.4	1



#	ARTICLE	IF	CITATIONS
253	Ultrasound Determination of Prostate Volume: Comparison of Transrectal (Ellipsoid v Planimetry) and Suprapubic Methods. <i>Journal of Endourology</i> , 1991, 5, 251-254.	1.1	23
254	Flutamide in treatment of benign prostatic hypertrophy. <i>Urology</i> , 1989, 34, 64-68.	0.5	38
255	Bilateral Ureteral Necrosis and Obliteration Secondary to Pancreatic Pseudocyst. <i>Journal of Urology</i> , 1988, 140, 1523-1525.	0.2	9
256	Prostatic Specific Antigen, Prostatic Acid Phosphatase and Acid Phosphatase in Patients with Prostate Cancer and Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1987, 137, .	0.2	0
257	Sex Hormones in Patients with Benign Prostatic Hyperplasia: A Comparison of Prostate Volume with Steroid Hormone Levels. <i>Journal of Urology</i> , 1987, 137, .	0.2	0
258	Hypogonadism in Prader-Willi syndrome. <i>Urology</i> , 1987, 29, 207-208.	0.5	8
259	Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. <i>Prostate</i> , 1986, 9, 311-318.	1.2	57
260	Renal Capsular Lipoma. <i>Journal of Urology</i> , 1985, 134, 118-119.	0.2	7
261	Mineralocorticoid Excess Secondary to Adrenal Cortical Carcinoma. <i>Journal of Urology</i> , 1984, 132, 962-965.	0.2	19
262	Gynecologic Injury in the Nongravid Female during Blunt Abdominal Trauma. <i>Journal of Trauma</i> , 1984, 24, 626-627.	2.3	15
263	Granular Cell Tumor of Penis. <i>Journal of Urology</i> , 1983, 130, 575-575.	0.2	13